Abstract
Abnormalities in steroid hormones are responsible for the development and prevention of endocrine diseases. Due to their biochemical roles in endocrine system, the quantitative evaluation of steroid hormones is needed to elucidate altered expression of steroids. Gas chromatographic-mass spectrometric (GC-MS) profiling of 70 urinary steroids, containing 22 androgens, 18 estrogens, 15 corticoids, 13 progestins, and 2 sterols, were validated and its quantitative data were visualized using hierarchically clustered heat maps to allow “steroid signatures”. The devised method provided a good linearity (r 2 > 0.994) with the exception of cholesterol (r 2 = 0.983). Precisions (% CV) and accuracies (% bias) ranged from 0.9% to 11.2% and from 92% to 119%, respectively, for most steroids tested. To evaluate metabolic changes, this method was applied to urine samples obtained from 59 patients with benign prostatic hyperplasia (BPH) versus 41 healthy male subjects. Altered concentrations of urinary steroids found and heat maps produced during this 70-compound study showed also differences between the ratios of steroid precursors and their metabolites (representing enzyme activity). Heat maps showed that oxidoreductases clustered (5β-reductase, 3β-HSD, 3β-HSD, and 17β-HSD, except for 20β-HSD). These results support that data transformation is valid, since 5β-reductase is a marker of BPH and 17β-HSD is positively expressed in prostate cells. Multitargeted profiling analysis of steroids generated quantitative results that help to explain correlations between enzyme activities. The data transformation and visualization described may to be found in the integration with the mining biomarkers of hormone-dependent diseases.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Nicholson, J.; Lindon, J.; Holmes, E. ‘Metabonomics’: Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29, 1181–1189.
Kaddurah-Daouk, R.; Kristal, B. S.; Weinshilboum, R. M. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 2008, 48, 653–683.
Dalle-Donne, I.; Rossi, R.; Colombo, R.; Giustarini, D.; Milzani, A. Biomarkers of oxidative damage in human disease. Clin. Chem. 2006, 52, 601–623.
Lee, S. H.; Woo, H. M.; Jung, B. H.; Lee, J. A.; Kwon, O. S.; Pyo, H. S.; Choi, M. H.; Chung, B. C. Metabolomic approach to evaluate the toxicological effects of nonylphenol with rat urine. Anal. Chem. 2007, 79, 6102–6110.
Falk, R. T.; Xu, X.; Keefer, L.; Veenstra, T. D.; Ziegler, R. G. A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 3411–3418.
Cho, H.-J.; Kim, J. D.; Lee, W.-Y.; Chung, B. C.; Choi, M. H. Quantitative metabolic profiling of 21 endogenous corticosteroids in urine by liquid chromatography-triple quadrupole-mass spectrometry. Anal. Chim. Acta 2009, 632, 101–108.
Falkenstein, E.; Tillmann, H. C.; Christ, M.; Feuring, M.; Wehling, M. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol. Rev. 2000, 52, 513–555.
Choi, M. H.; Hahm, J. R.; Jung, B. H.; Chung, B. C. Measurement of corticoids in the patients with clinical features indicative of mineralocorticoid excess. Clin. Chim. Acta 2002, 320, 95–99.
Caulfield, M. P.; Lynn, T.; Gottschalk, M. E.; Jones, K. L.; Taylor, N. F.; Malunowicz, E. M.; Shackleton, C. H. L.; Reitz, R. E.; Fisher, D. A. The diagnosis of congenital adrenal hyperplasia in the newborn by gas chromatography/mass spectrometry analysis of random urine specimens. J. Clin. Endocrinol. Metabol. 2002, 87, 3682–3690.
Choi, M. H.; Yoo, Y. S.; Chung, B. C. Biochemical roles of testosterone and epitestosterone to 5β-reductase as indicators of male-pattern baldness. J. Invest. Dermatol. 2001, 116, 57–61.
Wong, T.; Shackleton, C. H.; Covey, T. R.; Ellis, G. Identification of the steroids in neonatal plasma that interfere with 17β-hydroxyprogesterone radioimmunoassays. Clin. Chem. 1992, 38, 1830–1837.
Minutti, C. Z.; Lacey, J. M.; Magera, M. J.; Hahn, S. H.; McCann, M.; Schulze, A.; Cheillan, D.; Dorche, C.; Chace, D. H.; Lymp, J. F.; Zimmerman, D.; Rinaldo, P.; Matern, D. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J. Clin. Endocrinol. Metabol. 2004, 89, 3687–3693.
Nelson, R. E.; Grebe, S. K.; O’Kane, D. J.; Singh, R. J. Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin. Chem. 2004, 50, 373–384.
Santen, R. J.; Demers, L.; Ohorodnik, S.; Settlage, J.; Langecker, P.; Blanchett, D.; Goss, P. E.; Wang, S. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007, 72, 666–671.
Hsing, A. W.; Stanczyk, F. Z.; Bélanger, A.; Schroeder, P.; Chang, L.; Falk, R. T.; Feras, T. R. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol. Biomarkers. Prev. 2007, 16, 1004–1008.
Wood, L.; Ducroq, D. H.; Fraser, H. L.; Gillingwater, S.; Evans, C.; Pickett, A. J.; Rees, D. W.; John, R.; Turkes, A. Measurement of urinary free cortisol by tandem mass spectrometry and comparison with results obtained by gas chromatography-mass spectrometry and two commercial immunoassays. Ann. Clin. Biochem. 2008, 45, 380–388.
Palermo, M.; Gomez-Sanchez, C.; Roitman, E.; Shackleton, C. H. L. Quantitation of cortisol and related 3-oxo-4-ene steroids in urine using gas chromatography/mass spectrometry with stable isotope-labeled internal standards. Steroids 1996, 61, 583–589.
Homma, K.; Hasegawa, T.; Masumoto, M.; Takeshita, E.; Watanabe, K.; Chiba, H.; Kurosawa, T.; Takahashi, T.; Matsuo, N. Reference values for urinary steroids in Japanese newborn infants: gas chromatography/mass spectrometry in selected ion monitoring. Endocrinol. J. 2003, 50, 783–792.
Meffre, D.; Pianos, A.; Liere, P.; Eychenne, B.; Cambourg, A.; Schumacher, M.; Stein, D. G.; Guennoun, R. Steroid profiling in brain and plasma of male and pseudopregnant female rats after traumatic brain injury: analysis by gas chromatography/mass spectrometry. Endocrinology 2007, 148, 2505–2517.
Moon, J.-Y.; Jung, H.-J.; Moon, M. H.; Chung, B. C.; Choi, M. H. Inclusion complex-based solid-phase extraction of steroidal compounds with entrapped beta-cyclodextrin polymer. Steroids 2008, 73, 1090–1097.
Semmes, O. J. Defining the role of mass spectrometry in cancer diagnostics. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 1555–1557.
Rhodes, D. R.; Chinnaiyan, A. M. Integrative analysis of the cancer transcriptome. Nat. Genet. 2005, 37, S31-S37.
Ivshina, A. V.; Geroge, J.; Senko, O.; Mow, B.; Putti, T. C.; Smeds, J.; Lindahl, T.; Pawitan, Y.; Hall, P.; Nordgren, H.; Wong, J. E. L.; Liu, E. T.; Bergh, J.; Kuznetxov, V. A.; Miller, L. D. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66, 10292–10301.
Ray, S.; Britschgi, M.; Herbert, C.; Takeda-Uchimura, Y.; Boxer, A.; Blennow, K.; Friedman, L. F.; Galasko, D. R.; Jutel, M.; Karydas, A.; Kaye, J. A.; Leszek, J.; Miller, B. L.; Minthon, L.; Quinn, J. F.; Rabinovici, G. D.; Robinson, W. H.; Sabbagh, M. N.; So, Y. T.; Sparks, D. L.; Tabaton, M.; Tinklenberg, J.; Yesavaga, J. A.; Tibschirani, R.; Wyss-Coray, T. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat. Med. 2007, 13, 1359–1362.
Denkert, C.; Budczies, J.; Kind, T.; Weichert, W.; Tablack, P.; Sehouli, J.; Niesporek, S.; Konsgen, D.; Dietel, M.; Fiehn, O. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006, 66, 10795–10804.
Dettmer, K.; Aronov, P. A.; Hammock, B. D. Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 2007, 26, 51–78.
Choi, M. H.; Kim, J. N.; Chung, B. C. Rapid HPLC-electrospray tandem mass spectrometric assay for urinary testosterone and dihydrotestosterone glucuronides from patients with benign prostate hyperplasia. Clin. Chem. 2003, 49, 322–325.
McPherson, S. J.; Ellem, S. J.; Simpsn, E. R.; Patchev, V.; Fritzemeier, K.-H.; Risbridger, G. P. Essential role for estrogen receptor β in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 2007, 148, 566–574.
Luu-The, V.; Bélanger, A.; Labrie, F. Androgen biosynthetic pathways in the human prostate. Best Pract. Res. Clin. Endocrinol. Metabol. 2008, 22, 207–221.
Cho, Y.-D.; Choi, M. H. Alternative sample preparation techniques in gas chromatographic-mass spectrometric analysis of urinary androgenic steroids. Bull. Korean Chem. Soc. 2006, 27, 1315–1322.
Husdan, H.; Rapoport, A. Estimation of creatinine by the Jaffe reaction: A comparison of three methods. Clin. Chem. 1968, 14, 222–238.
Choi, M. H.; Kim, K.-R.; Hong, J. K.; Park, S. J.; Chung, B. C. Determination of nonsteroidal estrogens in breast milk, plasma, urine, and hair by gas chromatography/mass spectrometry. Rapid Commun. Mass. Spectrom. 2002, 16, 2221–2228.
Reddy, S.; Iden, C. R.; Brownawell, B. J. Analysis of steroid conjugates in sewage influent and effluent by liquid chromatography-tandem mass spectrometry. Anal. Chem. 2005, 77, 7032–7038.
Xu, X.; Veenstra, T. D.; Fox, S. D.; Roman, J. M.; Issaq, H. J.; Falk, R.; Saavedra, J. E.; Keefer, L. K.; Ziegler, R. G. Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal. Chem. 2005, 77, 6646–6654.
Bolton, J. L.; Thatcher, G. R. J. Potential mechanisms of estrogen quinone carcinogenesis. Chem. Res. Toxicol. 2008, 21, 93–101.
Wright, F.; Poizat, R.; Bongini, M.; Bozzolan, F.; Doukani, A.; Mauvais-Jarvis, P. Decreased urinary 5β-androstane-3α, 17 β-diol glucuronide excretion in patients with benign prostatic hyperplasia. J. Clin. Endocriol. Metabol. 1985, 60, 294–298.
Bauman, D. R.; Steckelbroeck, S.; Peehl, D. M.; Penning, T. M. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. J. Clin. Endocriol. Metabol. 2006, 147, 5806–5816.
Tsurusaki, T.; Aoki, D.; Kanetake, H.; Inoue, S.; Muramatsu, M.; Hishikawa, Y.; Koji, T. Zone-dependent expression of estrogen receptors & ;α and β in human benign prostatic hyperplasia. J. Clin. Endocriol. Metabol. 2003, 88, 1333–1340.
Prins, G. S.; Korach, K. S. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008, 73, 233–244.
Martel, C.; Rhéaume, E.; Takahashi, M.; Trudel, C.; Couét, J.; Luu-The, V.; Simard, J.; Labrie, F. Distribution of 17 β-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J. Steroid Biochem. Mol. Biol. 1992, 41, 597–603.
Délos, S.; Carsol, J.-L.; Fina, F.; Raynaud, J.-P.; Martin, P.-M. 5 β-Reductase and 17 β-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate. Int. J. Cancer 1998, 75, 840–846.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published online May 5, 2009
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Moon, JY., Jung, HJ., Moon, M.H. et al. Heat-map visualization of gas chromatography-mass spectrometry based quantitative signatures on steroid metabolism. J Am Soc Mass Spectrom 20, 1626–1637 (2009). https://doi.org/10.1016/j.jasms.2009.04.020
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.jasms.2009.04.020